Divalproex Sodium 250/500 Extended Release Tablet Extended Release Tablet First line in acute mania and maintenance therapy A significant reduction in the YMRS and CGI-BP scores from baseline to visit-3, in Indian patients with bipolar I disorder in continuation phase VS Lithium: Significantly lower risk of psychiatric hospitalization ■ Benefits a broader spectrum of bipolar conditions • Long-term safety and tolerability profile in adults & adolescents with migraine Epilepsy Bipolar Disorder Prophylaxis of Migraine
Back to Products